European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a blank-check company formed to pursue a business combination in the European life sciences and biotechnology sector. The SPAC completed its initial public offering in 2021 and has been focused on identifying acquisition targets within the European biotech landscape. EBAC filed an 8-K with the Securities and Exchange Commission on February 28, 2023, under accession number 0001193125-23-053836, reflecting a material corporate event during its search period. The vehicle targets the growing European biotech space, which has seen significant deal activity as sponsors seek to bring innovative life sciences companies to U.S. public markets. Visit SpacDesk and sign up for full data, filings history, and real-time deal tracking on EBAC and hundreds of other active SPACs.